Strategies to Counteract Resistance Mechanisms in CAR+ T-Cell-Based Immunotherapy for Triple-Negative Breast Cancer
Abstract
The lack of effective therapies for the treatment of metastatic triple negative breast cancer (TNBC) has prompted us to develop a combinatorial strategy for the treatment of this highly malignant type of breast cancer. In this strategy, the tumor antigen chondroitin sulphate proteoglycan 4 (CSPG4) is used as a target, since it is expressed on both differentiated TNBC cells and TNBC cancer initiating cells (CICs) and has a restricted distribution in normal tissues. Therefore, immunotargeting of CSPG4 is not expected to cause major side effects because of targeting of normal tissues and is expected to eliminate not only differentiated TNBC cells, but also TNBC CICs. According to the cancer stem cell theory, CICs play a major role in disease recurrence and in metastatic spreading. The effector mechanism is represented by T cells transduced with CSPG4-specificchimeric antigen receptor (CAR), since i) this strategy allows rapid generation of polyclonal T cells with tumor antigen (TA)-specificity and ii) the recognition of tumor cells by CAR T cells does not depend on HLA class I antigen expression by target cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2017
- Accession Number
- AD1055176
Entities
People
- Gianpietro Dotti